Cumulative savings of about 250 billion yuan!

The implementation of mass procurement not only reduces the price of medicines, but also improves the quality of medicines used by the masses
.
Data shows that from 2018 to the present, the state has organized five batches of drugs to be purchased in a centralized manner, covering 218 varieties, and the annual market volume before the centralized procurement reached 220 billion yuan
.
The implementation of centralized procurement has significantly reduced the prices of commonly used drugs for the treatment of common diseases such as high blood pressure, diabetes, hyperlipidemia, cancer, and mental diseases, with an average drop of more than 50%.
The burden of medication for patients has been significantly reduced, and the pressure on medical insurance funds has also been greatly eased.

.
According to relevant statistics, as of September 2021, since the reform of centralized procurement, cumulative savings have been about 250 billion yuan
.
Recently, the "Blue Book on the Progress and Effectiveness of Medical Insurance Drug Administration Reform" jointly issued by the Chinese Pharmaceutical Association and the China Medical Insurance Research Association also stated that in the past three years, the use of drugs in China's medical insurance catalogue has continued to increase, and the structure of medical institutions has become more reasonable; The price of medicines has dropped and the amount of medicines increased, and the quality of patients' medicines has improved
.
So how much cheaper drugs have been taken by the people in the three years of national drug procurement? Taking hypertension drugs as an example, there are 21 types of drugs included in centralized procurement, accounting for more than 50% of the market size of antihypertensive drugs.
Among them, the widely used amlodipine besylate tablets have been reduced by 79%, and the annual treatment cost has been reduced from the original 300 yuan.
To 60 yuan
.
There are 15 types of diabetes drugs included in the centralized collection, and the average price reduction after the collection is 69%, while the widely used metformin hydrochloride tablets are reduced by 53%
.
Take the hepatitis B treatment drug tenofovir as an example.
The pre-collection price was 10.
61 yuan/tablet, and the annual treatment cost was 3800 yuan.
After the collection, the price dropped to an average of 0.
38 yuan/tablet, a drop of 96%, and the one-year treatment cost was reduced.
To 137 yuan
.
The average annual treatment cost of entecavir decreased from 5,500 yuan to 70 yuan; the average annual treatment cost of tenofovir dipivoxil decreased from 6,000 yuan to about 150 yuan
.
In addition, the price of gefitinib, a tumor treatment drug that has attracted much attention from the market, dropped from 132 yuan/tablet to an average of 41.
8 yuan/tablet, a decrease of 69%.
The annual treatment fee was controlled from the original 47,000 yuan or more.
About 15,000 yuan, and after the medical insurance reimbursement, the individual patient only bears about 6,000 yuan
.
Centralized procurement and capacity expansion, drug price reduction.
.
.
The overall level of medical service prices in China has been effectively regulated, drug prices have returned to a reasonable level, and problems such as expensive medical care are being effectively alleviated
.
According to the industry, in the future, with the normalization and institutionalization of the centralized procurement of drugs organized by the state, more and more drugs will be included in the scope of centralized procurement, and the problem of "expensive medical treatment" will be further solved
.
The advancement of centralized procurement has caused tremendous changes in the competitive landscape of the pharmaceutical industry, but its dividends not only benefit the civilian population, but also save transaction costs for pharmaceutical companies and promote rapid adjustment of the business lines of pharmaceutical companies
.
According to relevant data, a number of pharmaceutical companies in the first half of this year, such as CSPC, Kelun Pharmaceutical, China Biopharmaceuticals, and Sinopharm Group, have achieved substantial revenue growth and a significant increase in market share through centralized procurement
.
Among them, CSPC Group's Keraili, as the second round of centralized procurement, increased its volume significantly after entering the centralized procurement, and achieved a sales growth of 17.
9% even after the price was reduced by 68.
9%
.
Two years after the company's cardiovascular drug Encun (clopidogrel bisulfate tablets) entered the centralized procurement and implementation, its sales revenue increased by 35.
5% year-on-year
.
According to its financial report data, in the first half of 2021, the company's revenue increased by about 10% year-on-year to 13.
822 billion yuan; net profit increased by about 32% year-on-year to 3.
063 billion yuan
.
Some analysts also pointed out that with the advancement of centralized procurement, the profit margin of generic drugs has been compressed, and various pharmaceutical companies have begun to invest in the research and development of innovative drugs
.
According to relevant data, in 2020, the R&D expenses of listed A-share pharmaceutical companies will increase by 22% year-on-year
.
window.
_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: accumulated savings of about 250 billion yuan! Five batches of centralized procurement have effectively alleviated the problems of expensive medical treatment, and purchases in large quantities Good Time [Information Search] [Add to Favorites] [Tell a Friend] [Print this article] [Close Window] There are 0 pieces of similar information [View All] Related Comments com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: accumulated savings of about 250 billion yuan! Five batches of centralized procurement have effectively alleviated the problems of expensive medical treatment, and purchases in large quantities Good Time [Information Search] [Add to Favorites] [Tell a Friend] [Print this article] [Close Window] There are 0 pieces of similar information [View All] Related Comments com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: accumulated savings of about 250 billion yuan! Five batches of centralized procurement have effectively alleviated the problems of expensive medical treatment, and purchases in large quantities Good Time [Information Search] [Add to Favorites] [Tell a Friend] [Print this article] [Close Window] There are 0 pieces of similar information [View All] Related Comments